More News! GSK’s Pipeline Shakeup, Bayer’s Failure & an EU Investigation

Try as we might, we can’t cover all the biotech news out there! Here’s a roundup of news that didn’t make the cut this week.

Oleksii G
  • Bayer’s ADC for mesothelioma failed in Phase II, collaterally denting the stocks of its partners MorphoSys and ImmunoGen
  • Themis has kicked off a Phase II study of its Chikungunya vaccine in Puerto Rico, where the disease is endemic

Brian Lasenby

  • Do presubmission meetings with the EMA open the door for drugmakers to influence MAA decisions? The EU is investigating.
  • Emma Walmsley, GSK’s CEO, is making big moves to overhaul the pharma’s pipeline

Images from Brian Lasenby, Nirun Thuwasin, Marco Diaz Segura, Oleksii G, Janossy Gergely, Vladimir Wrangel / shutterstock.com

Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.

We use cookies to give you the best experience and for advertising purposes. By accepting, you support our independent media and its' freely accessible content.